Is UNH a buy, hold, or sell?
UNH carries a valuation grade of Reduce. The trailing P/E of 30.7 sits 39% above the Healthcare sector median of 22.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $308–$552 — implying a +6% margin of safety at the current price of $407.46. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 9% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 9.5% earnings surprise. Analyst estimate revisions are trending upward.
What are UNH's key risk factors?
With a beta of 0.65, UNH exhibits a defensive risk profile relative to the broad market. The 95th-percentile CVaR of -24.0% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 2.4% of total portfolio loss in the worst 5% of months. Net margins of 2.7% fall below the Healthcare sector average of 18%, suggesting margin pressure. The balance sheet is conservatively leveraged at 74% debt-to-equity.
Implied volatility of 1.9% is below realized volatility of 28.3%, potentially making options relatively cheap. Insider transactions show net buying of $36.9M over the trailing period, a signal often associated with management confidence. Short interest is low at 2.4% of float, suggesting limited bearish conviction.
How does UNH fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — UNH carries a beta of 0.65, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all reduceings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, UNH shows the strongest co-movement with LLY (0.15), PFE (0.12), ABBV (0.09). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all reduceings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The UNH analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning UNH’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
